A Agilent Technologies, Inc.
A Agilent Technologies, Inc.
Healthcare · Diagnostics & Research
Market read
Scan convergence 1 scan as of 2026-08-14 1 bull converging
POC $136.92 · VWAP $129.90 · +14.3% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
2 watchlists
A Price Structure
Loading timeframes…
Peers
Every watchlist A belongs to, members best 30-day change first — A highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@biotech-scan
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-04-30: revenue $1.83B, diluted EPS $1.20, net income $339M (SEC filing). Across the print the stock moved +17.6% (close before → first close after).
full note →Against street estimates
How A's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
A research tape
14 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.